We serve Chemical Name:(3Z)-1-(2-butenyloxy)-3-Hexene CAS:888744-18-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(3Z)-1-(2-butenyloxy)-3-Hexene
CAS.NO:888744-18-1
Synonyms:(Z)-1-((but-2-en-1-yl)oxy)hex-3-ene;3-Hexene, 1-(2-butenyloxy)-,(3Z)-
Molecular Formula:C10H18O
Molecular Weight:154.24900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:9.23000
Exact Mass:154.13600
LogP:2.93540
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (Z)-1-((but-2-en-1-yl)oxy)hex-3-ene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Hexene, 1-(2-butenyloxy)-,(3Z)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Hexene, 1-(2-butenyloxy)-,(3Z)- Use and application,3-Hexene, 1-(2-butenyloxy)-,(3Z)- technical grade,usp/ep/jp grade.
Related News: A multitude of enzymes is now utilized for generating active pharmaceutical ingredients (APIs) and intermediates for their production, with such reagents offering numerous advantages compared to using traditional metal catalysts. tert-butyl 4-(3-aminopyridin-4-yl)piperazine-1-carboxylate manufacturers Wavelength Pharmaceuticals will pay an undisclosed sum to buy up a majority stake in Hyderabad’s Vanamali Organics, an Indian firm specializing in making drug intermediates and starting materials that will add to Wavelengths’ API contract manufacturing work, the company said in a release. Ethyl 2-bromo-5-nitrobenzoate suppliers A multitude of enzymes is now utilized for generating active pharmaceutical ingredients (APIs) and intermediates for their production, with such reagents offering numerous advantages compared to using traditional metal catalysts. 2-Methyl-3,4-dihydro-2H-1,4-benzothiazine vendor & factory A multitude of enzymes is now utilized for generating active pharmaceutical ingredients (APIs) and intermediates for their production, with such reagents offering numerous advantages compared to using traditional metal catalysts. ,CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication.
